Exact Mass: 453.1999
Exact Mass Matches: 453.1999
Found 500 metabolites which its exact mass value is equals to given mass value 453.1999
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
20-Oxo-leukotriene E4
20-oxo-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-oxo-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)
2-(3-(2-Aminoethyl)-1h-indol-5-yloxy)acetyl-l-tyrosyl-glycinamide
7-Hydroxyfluphenazine
Fluphenazine sulfoxide
Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
2-[[N-Methyl-N-[5-guanidino-2-[(2-amino-3-methylbutyryl)amino]pentanoyl]hydrazino]phosphonyl]-2-hydroxyacetic acid methyl ester
Ala Cys Phe Asn
Ala Cys Asn Phe
Ala Phe Cys Asn
Ala Phe Asn Cys
Ala His Ile Asn
Ala His Leu Asn
Ala His Asn Ile
Ala His Asn Leu
Ala His Gln Val
Ala His Val Gln
Ala Ile His Asn
Ala Ile Asn His
Ala Leu His Asn
Ala Leu Asn His
Ala Asn Cys Phe
Ala Asn Phe Cys
Ala Asn His Ile
Ala Asn His Leu
Ala Asn Ile His
Ala Asn Leu His
Ala Asn Ser Tyr
Ala Asn Tyr Ser
Ala Gln His Val
Ala Gln Val His
Ala Ser Asn Tyr
Ala Ser Tyr Asn
Ala Val His Gln
Ala Val Gln His
Ala Tyr Asn Ser
Ala Tyr Ser Asn
Cys Ala Phe Asn
Cys Ala Asn Phe
Cys Cys Lys Thr
Cys Cys Thr Lys
Cys Phe Ala Asn
Cys Phe Gly Lys
Cys Phe Gly Gln
Cys Phe Lys Gly
Cys Phe Asn Ala
Cys Phe Gln Gly
Cys Gly Phe Lys
Cys Gly Phe Gln
Cys Gly Lys Phe
Cys Gly Gln Phe
Cys Lys Cys Thr
Cys Lys Phe Gly
Cys Lys Gly Phe
Cys Lys Thr Cys
Cys Asn Ala Phe
Cys Asn Phe Ala
Cys Gln Phe Gly
Cys Gln Gly Phe
Cys Thr Cys Lys
Cys Thr Lys Cys
Phe Ala Cys Asn
Phe Ala Asn Cys
Phe Cys Ala Asn
Phe Cys Gly Lys
Phe Cys Gly Gln
Phe Cys Lys Gly
Phe Cys Asn Ala
Phe Cys Gln Gly
Phe Gly Cys Lys
Phe Gly Cys Gln
Phe Gly Lys Cys
Phe Gly Gln Cys
Phe Lys Cys Gly
Phe Lys Gly Cys
Phe Asn Ala Cys
Phe Asn Cys Ala
Phe Asn Ser Ser
Phe Gln Cys Gly
Phe Gln Gly Cys
Phe Ser Asn Ser
Phe Ser Ser Asn
Gly Cys Phe Lys
Gly Cys Phe Gln
Gly Cys Lys Phe
Gly Cys Gln Phe
Gly Phe Cys Lys
Gly Phe Cys Gln
Gly Phe Lys Cys
Gly Phe Gln Cys
Gly His Ile Gln
Gly His Leu Gln
Gly His Gln Ile
Gly His Gln Leu
Gly Ile His Gln
Gly Ile Gln His
Gly Lys Cys Phe
Gly Lys Phe Cys
Gly Lys Ser Tyr
Gly Lys Tyr Ser
Gly Leu His Gln
Gly Leu Gln His
Gly Asn Thr Tyr
Gly Asn Tyr Thr
Gly Gln Cys Phe
Gly Gln Phe Cys
Gly Gln His Ile
Gly Gln His Leu
Gly Gln Ile His
Gly Gln Leu His
Gly Gln Ser Tyr
Gly Gln Tyr Ser
Gly Ser Lys Tyr
Gly Ser Gln Tyr
Gly Ser Tyr Lys
Gly Ser Tyr Gln
Gly Thr Asn Tyr
Gly Thr Tyr Asn
Gly Tyr Lys Ser
Gly Tyr Asn Thr
Gly Tyr Gln Ser
Gly Tyr Ser Lys
Gly Tyr Ser Gln
Gly Tyr Thr Asn
His Ala Ile Asn
His Ala Leu Asn
His Ala Asn Ile
His Ala Asn Leu
His Ala Gln Val
His Ala Val Gln
His Gly Ile Gln
His Gly Leu Gln
His Gly Gln Ile
His Gly Gln Leu
His Ile Ala Asn
His Ile Gly Gln
His Ile Asn Ala
His Ile Gln Gly
His Leu Ala Asn
His Leu Gly Gln
His Leu Asn Ala
His Leu Gln Gly
His Asn Ala Ile
His Asn Ala Leu
His Asn Ile Ala
His Asn Leu Ala
His Asn Pro Ser
His Asn Ser Pro
His Pro Asn Ser
His Pro Ser Asn
His Gln Ala Val
His Gln Gly Ile
His Gln Gly Leu
His Gln Ile Gly
His Gln Leu Gly
His Gln Val Ala
His Ser Asn Pro
His Ser Pro Asn
His Val Ala Gln
His Val Gln Ala
Ile Ala His Asn
Ile Ala Asn His
Ile Gly His Gln
Ile Gly Gln His
Ile His Ala Asn
Ile His Gly Gln
Ile His Asn Ala
Ile His Gln Gly
Ile Asn Ala His
Ile Asn His Ala
Ile Gln Gly His
Ile Gln His Gly
Lys Cys Cys Thr
Lys Cys Phe Gly
Lys Cys Gly Phe
Lys Cys Thr Cys
Lys Phe Cys Gly
Lys Phe Gly Cys
Lys Gly Cys Phe
Lys Gly Phe Cys
Lys Gly Ser Tyr
Lys Gly Tyr Ser
Lys Ser Gly Tyr
Lys Ser Tyr Gly
Lys Thr Cys Cys
Lys Tyr Gly Ser
Lys Tyr Ser Gly
Leu Ala His Asn
Leu Ala Asn His
Leu Gly His Gln
Leu Gly Gln His
Leu His Ala Asn
Leu His Gly Gln
Leu His Asn Ala
Leu His Gln Gly
Leu Asn Ala His
Leu Asn His Ala
Leu Gln Gly His
Leu Gln His Gly
Asn Ala Cys Phe
Asn Ala Phe Cys
Asn Ala His Ile
Asn Ala Ser Tyr
Asn Ala Tyr Ser
Asn Cys Ala Phe
Asn Cys Phe Ala
Asn Phe Ala Cys
Asn Phe Cys Ala
Asn Phe Ser Ser
Asn Gly Thr Tyr
Asn Gly Tyr Thr
Asn His Pro Ser
Asn His Ser Pro
Asn Pro His Ser
Asn Pro Ser His
Asn Ser Ala Tyr
Asn Ser Phe Ser
Asn Ser His Pro
Asn Ser Pro His
Asn Ser Ser Phe
Asn Ser Tyr Ala
Asn Thr Gly Tyr
Asn Thr Tyr Gly
Asn Tyr Ala Ser
Asn Tyr Gly Thr
Asn Tyr Ser Ala
Asn Tyr Thr Gly
Pro His Asn Ser
Pro His Ser Asn
Pro Asn His Ser
Pro Asn Ser His
Pro Ser His Asn
Pro Ser Asn His
Gln Cys Phe Gly
Gln Cys Gly Phe
Gln Phe Cys Gly
Gln Phe Gly Cys
Gln Gly Cys Phe
Gln Gly Phe Cys
Gln Gly Ser Tyr
Gln Gly Tyr Ser
Gln Ser Gly Tyr
Gln Ser Tyr Gly
Gln Tyr Gly Ser
Gln Tyr Ser Gly
Ser Ala Asn Tyr
Ser Ala Tyr Asn
Ser Phe Asn Ser
Ser Phe Ser Asn
Ser Gly Lys Tyr
Ser Gly Gln Tyr
Ser Gly Tyr Lys
Ser Gly Tyr Gln
Ser His Asn Pro
Ser His Pro Asn
Ser Lys Gly Tyr
Ser Lys Tyr Gly
Ser Asn Ala Tyr
Ser Asn Phe Ser
Ser Asn His Pro
Ser Asn Pro His
Ser Asn Ser Phe
Ser Asn Tyr Ala
Ser Pro His Asn
Ser Pro Asn His
Ser Gln Gly Tyr
Ser Gln Tyr Gly
Ser Ser Phe Asn
Ser Ser Asn Phe
Ser Tyr Ala Asn
Ser Tyr Gly Lys
Ser Tyr Gly Gln
Ser Tyr Lys Gly
Ser Tyr Asn Ala
Ser Tyr Gln Gly
Thr Cys Cys Lys
Thr Cys Lys Cys
Thr Gly Asn Tyr
Thr Gly Tyr Asn
Thr Lys Cys Cys
Thr Asn Gly Tyr
Thr Asn Tyr Gly
Thr Tyr Gly Asn
Thr Tyr Asn Gly
Tyr Ala Asn Ser
Tyr Ala Ser Asn
Tyr Gly Lys Ser
Tyr Gly Asn Thr
Tyr Gly Gln Ser
Tyr Gly Ser Lys
Tyr Gly Ser Gln
Tyr Gly Thr Asn
Tyr Lys Gly Ser
Tyr Lys Ser Gly
Tyr Asn Ala Ser
Tyr Asn Gly Thr
Tyr Asn Ser Ala
Tyr Asn Thr Gly
Tyr Gln Gly Ser
Tyr Gln Ser Gly
Tyr Ser Ala Asn
Tyr Ser Gly Lys
Tyr Ser Gly Gln
Tyr Ser Lys Gly
Tyr Ser Asn Ala
Tyr Ser Gln Gly
Tyr Thr Gly Asn
Tyr Thr Asn Gly
Fluphenazine (further oxidation of piperazine ring)
20-Oxo-leukotriene E4
(S)-2-Fmoc-Amino-Heptanedioic Acid 7-Tert-Butyl Ester
Trioxifene
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
4-[3-(1-benzhydrylazetidin-3-yl)oxy-2-hydroxypropoxy]-1H-indole-2-carbonitrile
(2S,4S)-4-Diphenylphosphino 2-diphenylphosphinomethyl pyrrolidine
SB590885
SB-590885 is a potent?B-Raf?inhibitor with?Ki?of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.
Netarsudil
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
1H-1-Benzazepine-5-acetamide, 1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-N-(1-methylethyl)-, (R)-
Oclacitinib maleate
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Ethoheptazine citrate
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
N-[5-(1,1-Dioxidoisothiazolidin-2-YL)-1H-indazol-3-YL]-2-(4-piperidin-1-ylphenyl)acetamide
N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide
(20s)-19,20,22,23-Tetrahydro-19-oxo-5h,21h-18,20-ethano-12,14-etheno-6,10-methenobenz[d]imidazo[4,3-l][1,6,9,13]oxatriazacyclonoadecosine-9-carbonitrile
(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-5-hydroxy-20-oxoicosa-7,9,11,14-tetraenoic acid
2-(3-(2-Aminoethyl)-1h-indol-5-yloxy)acetyl-l-tyrosyl-glycinamide
Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
3-Demethylstaurosporinium(1+)
Conjugate acid of 3-demethylstaurosporine.
4-[4-(2,3,5,6-tetramethylphenyl)sulfonylpiperazine-1-carbonyl]-1H-quinolin-2-one
3-[[2-[[4-Ethyl-5-[(4-methylanilino)methyl]-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]benzoic acid ethyl ester
3,5-Dimethyl-1-phenyl-4-pyrazolecarboxylic acid [2-[4-amino-1-methyl-3-(2-methylpropyl)-2,6-dioxo-5-pyrimidinyl]-2-oxoethyl] ester
(3R,3aS,7R,7aS)-3-[3-(4-acetylphenyl)-4-fluorophenyl]-7-methyl-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one
(3R,3aR,7aR)-3-[4-(4-acetylphenyl)-2-fluorophenyl]-7a-methyl-2-(phenylmethyl)-3,3a,6,7-tetrahydroisoindol-1-one
(5aS,7S,8aR,9aS)-7,7,8,8-tetramethyl-5a-nitrospiro[1,2,3,5,6,8a,9,9a-octahydrocyclopenta[f]indolizine-7,3-1,8-dihydropyrano[2,3-g]indole]-2,9-dione
(E)-3,7,11,15-tetramethylhexadec-2-en-1-yl diphosphate(3-)
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide
3-butan-2-yl-1-[(6,7-dimethoxy-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-phenylethyl)thiourea
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(azepan-1-ylmethyl)-N-[(E)-(2-ethoxyphenyl)methylidene]-1H-1,2,3-triazole-4-carbohydrazide
1-(4-Amino-1,2,5-oxadiazol-3-YL)-N-[(E)-(2-ethoxyphenyl)methylidene]-5-[(4-methylpiperidin-1-YL)methyl]-1H-1,2,3-triazole-4-carbohydrazide
3-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
1-(4-Amino-1,2,5-oxadiazol-3-YL)-N-[(E)-(4-ethoxyphenyl)methylidene]-5-[(4-methylpiperidin-1-YL)methyl]-1H-1,2,3-triazole-4-carbohydrazide
Ethyl 4-oxo-4-[(18-phenyl-11-oxa-13,15-diazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,8,12,14,16-octaen-16-yl)amino]butanoate
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[[(2R,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
CID 23724790
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
1-[(1S)-2-[(2-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1R)-2-[(2-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
2-[(2R,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3S,6R)-3-(1,3-benzodioxol-5-ylcarbamoylamino)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
methyl (1S,9R,10R,11R)-5-[3-(dimethylcarbamoyl)phenyl]-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
2-[(2R,3R,6R)-3-(1,3-benzodioxol-5-ylcarbamoylamino)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,3R,6R)-3-(1,3-benzodioxol-5-ylcarbamoylamino)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
methyl (1R,9S,10S,11S)-5-[3-(dimethylcarbamoyl)phenyl]-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[[(2R,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2S,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2R,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
2-[(2S,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3R,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
N-[(2S,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
(3aR,4R,9bS)-8-(1-cyclohexenyl)-N-(2,5-difluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
4-[(3aS,4R,9bS)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aR,4S,9bR)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
[(3aR,4S,9bS)-4-(hydroxymethyl)-8-[2-(4-methoxyphenyl)ethynyl]-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-pyridin-4-ylmethanone
(6R,7R,8S)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
1-[(1R)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
N-[[(2S,3R)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2R,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2S,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
N-[[(2S,3S)-8-[2-(4-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylacetamide
1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
2-[(2S,3R,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,3R,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide
N-[(2R,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
(2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
4-[(3aR,4R,9bR)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aS,4S,9bS)-1-[1,3-benzodioxol-5-yl(oxo)methyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
(6S,7S,8S)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one
1-[(1S)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
1-[(1S)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-4-(2-pyridin-3-ylacetyl)-1,4-diazabicyclo[4.2.0]octan-2-one
1-[(1S)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
1-[(1R)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
[(1S)-2-(cyclopropylmethyl)-1-[(2,5-difluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
2-[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)diazenyl]-3-oxo-N,3-diphenylpropanamide
5-aminopentyl 3-O-(2-O-acetyl-6-deoxy-alpha-L-talopyranosyl)-beta-D-glucopyranoside
2-amino-3-[hydroxy-[2-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
20-oxoleukotriene E4
A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding aldehyde
BI-6901
BI 6901 is a potent, selective CCR10 antagonist (pIC50=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research[1].
Phe-Pro-Ala-pNA
Phe-Pro-Ala-pNA is a chromogenic substrate of tripeptidyl peptidase. Phe-Pro-Ala-pNA can be used to test tripeptidyl peptidase activity[1].
Temuterkib
Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.